These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19128207)

  • 1. Alzheimer's disease drug development: old problems require new priorities.
    Becker RE; Greig NH
    CNS Neurol Disord Drug Targets; 2008 Dec; 7(6):499-511. PubMed ID: 19128207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.
    Becker RE; Greig NH
    Curr Alzheimer Res; 2008 Aug; 5(4):346-57. PubMed ID: 18690832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
    Becker RE; Greig NH; Giacobini E
    J Alzheimers Dis; 2008 Oct; 15(2):303-25. PubMed ID: 18953116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Donohue MC; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw L; Thompson PM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jul; 11(7):865-84. PubMed ID: 26194320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing the success rate for Alzheimer's disease drug discovery and development.
    Becker RE; Greig NH
    Expert Opin Drug Discov; 2012 Apr; 7(4):367-70. PubMed ID: 22439785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in pharmacology and drug discovery.
    Anderson DC; Kodukula K
    Biochem Pharmacol; 2014 Jan; 87(1):172-88. PubMed ID: 24001556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing the value of diagnostics in Alzheimer's disease drug development.
    Snyder EM; Olin J; David FS
    Nat Rev Drug Discov; 2012 Mar; 11(3):183-4. PubMed ID: 22378261
    [No Abstract]   [Full Text] [Related]  

  • 10. [Preclinical AD and Biomarker; from J-ADNI to AMED Preclinical Study].
    Suzuki K
    Brain Nerve; 2017 Jul; 69(7):691-700. PubMed ID: 28739982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why so few drugs for Alzheimer's disease? Are methods failing drugs?
    Becker RE; Greig NH
    Curr Alzheimer Res; 2010 Nov; 7(7):642-51. PubMed ID: 20704560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
    Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to drug discovery and development for Alzheimer disease.
    Fillit HM; O'Connell AW; Brown WM; Altstiel LD; Anand R; Collins K; Ferris SH; Khachaturian ZS; Kinoshita J; Van Eldik L; Dewey CF
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S1-8. PubMed ID: 12070355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.
    Hampel H; Vergallo A; Caraci F; Cuello AC; Lemercier P; Vellas B; Giudici KV; Baldacci F; Hänisch B; Haberkamp M; Broich K; Nisticò R; Emanuele E; Llavero F; Zugaza JL; Lucía A; Giacobini E; Lista S;
    Neuropharmacology; 2021 Mar; 185():108081. PubMed ID: 32407924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of metabolomics in drug discovery and development.
    Wishart DS
    Drugs R D; 2008; 9(5):307-22. PubMed ID: 18721000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development.
    Arai H; Okamura N; Furukawa K; Kudo Y
    Tohoku J Exp Med; 2010 Jun; 221(2):87-95. PubMed ID: 20467230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
    Conrado DJ; Duvvuri S; Geerts H; Burton J; Biesdorf C; Ahamadi M; Macha S; Hather G; Francisco Morales J; Podichetty J; Nicholas T; Stephenson D; Trame M; Romero K; Corrigan B;
    Clin Pharmacol Ther; 2020 Apr; 107(4):796-805. PubMed ID: 31955409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.